Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EBITDA Margin % Related Terms
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EBITDA Margin % Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
IST:GENIL vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS EBITDA Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a EBITDA Margin % of 13.62% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is 30% above median its historical median of 10.47. Over the past decade, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EBITDA Margin % has ranged from 6.96 to 19.10. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #434 out of 952 companies in the Drug Manufacturers industry, placing it in the top 45.6%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EBITDA Margin % too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EBITDA Margin % of 13.62% is 30% above median its 10-year median of 10.47. Over the past 10 years, this metric has ranged from a low of 6.96 to a high of 19.10. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 13.62% is 9.2% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #434 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #434 out of 952 companies for EBITDA Margin %. This puts Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 13.62% is 9.2% above this benchmark. Historically, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's own EBITDA Margin % has ranged from 6.96 to 19.10 over the past decade. While the company's 10-year median is 10.47 vs. the industry median of 12.47, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EBITDA Margin % of 13.62% is 9.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current EBITDA Margin % is 13.62%, which is 30% above median its own 10-year median of 10.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺8.12, compared to a current price of ₺9.32 — trading 14.8% above its estimated fair value. The current EBITDA Margin % is 13.62%, which is 30% above median its 10-year median of 10.47 and 9.2% above the Drug Manufacturers industry median of 12.47. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current EBITDA Margin % is 13.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺9.32 is trading 14.8% above its estimated GF Value™ of ₺8.12.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:GENIL:
EBITDA Margin %: 13.62% (30% above median its 10-year median of 10.47)
GF Value™: ₺8.12 vs. price of ₺9.32 (14.8% above fair value)
Industry Position: 9.2% above the Drug Manufacturers median (#434 of 952)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Business Description
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
86GF Score
Get the complete analysis for IST:GENIL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
